Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs VanEck Junior Gold Miners (GDXJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs VanEck Junior Gold Miners — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.81 (market cap $39.89B), while VanEck Junior Gold Miners trades at $96.03. The key difference: VanEck Junior Gold Miners is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | GDXJ | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $491.22 | $156.19 |
52-Week Low | $278.09 | $64.22 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
GDXJ trades at $98.91, down 0.06% on the day, with a bearish technical outlook as moving averages signal selling pressure and key support lies at $97. The ETF has underperformed peers in 2026, with Seeking Alpha noting double-digit declines amid concerns over its small-cap exposure and portfolio overlap. Recent news highlights investor caution toward junior gold miners compared to senior counterparts.
The investment case remains challenged by weak sentiment and technical headwinds, though potential exists as a hedge during market corrections. Risks include Federal Reserve policy impacts on gold prices and competition from other mining ETFs. Wall Street sentiment is cautious, with no bullish analyst signals evident in recent data.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →
